Eustachio D'ERrico

Dr. Eustachio D'ERrico

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2018 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
ASAntonio Scarafino
Antonio Scarafino
EDEustachio D'ERrico
Eustachio D'ERrico
AIAlessandro Introna
Alessandro Introna
AFAngela Fraddosio
Angela Fraddosio
EDEugenio Distaso
Eugenio Distaso
ISIsabella Laura Simone
Isabella Laura Simone

13 August 2021 in Clinical Drug Investigation
Verified
Journal Article
Open access
PDF file
GMGiammarco Milella
Giammarco Milella
AIAlessandro Introna
Alessandro Introna
EDEustachio D'ERrico
Eustachio D'ERrico
AFAngela Fraddosio
Angela Fraddosio
GSGaspare Scaglione
Gaspare Scaglione
ISIsabella Laura Simone
Isabella Laura Simone
Background and Objectives Nusinersen was approved as the first disease-modifying therapy in spinal muscular atrophy (SMA). Our aim was to analyse therapy-related changes in cerebrospinal fluid (CSF) and serum parameters of adult type 2–3 SMA and to correlate biochemical data with motor functional status. Methods Nine adult SMA type 2–3 patients and ten control subjects without neurodegenerative diseases were included in our single-centre study. Cross-sectional analysis of CSF routine parameters, CSF neurofilament light chain, CSF Tau, CSF phospho-Tau and serum creatinine was performed between SMA patients at baseline (T0) and control subjects. The above-mentioned fluid parameters were longitudinally analysed in the SMA cohort after loading dose (T1) and after four maintenance doses (T2, T3, T4, T5). Hammersmith Functional Motor Scale Expanded (HFMSE), Revised Upper Limb Module (RULM) and the 6-minute walking test (6MWT) were used to evaluate motor outcomes. Results Improvements in HFMSE, RULM and 6MWT were observed only after the loading dose of nusinersen. No significant differences in routine CSF parameters and CSF markers of neurodegeneration were found between SMA patients and control subjects. Serum creatinine levels were significantly lower in SMA patients than in control subjects. CSF/serum albumin ratio (Qalb) significantly increased from T0 to each time point, without any further increase after the maintenance doses. Persistent systemic oligoclonal bands (OCBs) were found in five patients from baseline. Three more patients developed persistent systemic OCBs from T1; one patient showed intrathecal OCBSs from baseline to T5. Markers of neurodegeneration did not change during the follow-up and did not correlate with motor scores at baseline and at each timepoint. Serum creatinine levels significantly correlated with HFMSE and RULM at each time point. Conclusions The increase of the Qalb values and the development of systemic OCBs in some SMA patients could be due to repeated lumbar puncture and to the immunogenic effect of nusinersen. On the other hand, the presence of OCBs in serum and/or CSF at baseline should be further investigated. Furthermore, biomarkers of neurodegeneration did not play a prognostic role in our cohort of adult SMA patients.

2 March 2021 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
EDEugenio Distaso
Eugenio Distaso
GMGiammarco Milella
Giammarco Milella
DMDomenico Maria Mezzapesa
Domenico Maria Mezzapesa
AIAlessandro Introna
Alessandro Introna
EDEustachio D'ERrico
Eustachio D'ERrico
ISIsabella Laura Simone
Isabella Laura Simone
Background: Edaravone was approved as a new treatment for amyotrophic lateral sclerosis (ALS), although there are different opinions on its effectiveness. Magnetic resonance (MRI) measures appear promising as diagnostic and prognostic indicators of disease. However, published studies on MRI using to monitor treatment efficacy in ALS are lacking. Purpose: The objective of this study was to investigate changes in brain MRI measures in patients treated with edaravone. Methods: Thirteen ALS patients assuming edaravone (ALS-EDA) underwent MRI at baseline (T0) and after 6 months (T6) to measure cortical thickness (CT) and fractional anisotropy (FA) of white matter (WM) tracts. MRI data of ALS-EDA were compared at T0 with those of 12 control subjects (CS), and at T6 with those of 11 ALS patients assuming only riluzole (ALS-RIL), extracted from our ALS cohort using a propensity-score-matching. A longitudinal MRI analysis was performed in ALS-EDA between T6 and T0. Results: At T0, ALS-EDA showed a cortical widespread thinning in both hemispheres, particularly in the bilateral precentral gyrus, and a reduction of FA in bilateral corticospinal tracts, in comparison to CS. Thinning in bilateral precentral cortex and significant widespread reduction of FA in several WM tracts were observed in ALS-EDA at T6 compared to T0. At T6, no significant differences in MRI measures of ALS-EDA versus ALS-RIL were found. Conclusions: Patients treated with edaravone showed progression of damage in the motor cortex and several WM tracts, at a six-month follow-up. Moreover, this study showed no evidence of a difference between edaravone and riluzole.

6 April 2015 in Neurology
Verified
Journal Article
Closed access
RCRosa Cortese
Rosa Cortese
EDEustachio D'ERrico
Eustachio D'ERrico
AIAlessandro Introna
Alessandro Introna
GSGabriella Schirosi
Gabriella Schirosi
ASAntonio Scarafino
Antonio Scarafino
ISIsabella Laura Simone
Isabella Laura Simone

1 October 2020 in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Verified
Journal Article
Closed access
SZstefano zoccolella
stefano zoccolella
AIAlessandro Introna
Alessandro Introna
AMAntonella Mastronardi
Antonella Mastronardi
GIGiovanni Iliceto
Giovanni Iliceto
ASAntonio Scarafino
Antonio Scarafino
ISIsabella Laura Simone
Isabella Laura Simone
(2020). Inclusion of motor evoked abnormalities in amyotrophic lateral sclerosis: a diagnostic algorithm to early classify lower motor neuron phenotypes. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. Ahead of Print.

5 April 2016 in Neurology
Verified
Journal Article
Closed access
EDEugenio Distaso
Eugenio Distaso
DMDomenico Mezzapesa
Domenico Mezzapesa
EDEustachio D'ERrico
Eustachio D'ERrico
ASAntonio Scarafino
Antonio Scarafino
AIAlessandro Introna
Alessandro Introna
ISIsabella Laura Simone
Isabella Laura Simone